Lamisil at

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the treatment of most cases of jock itch (tinea cruris). It effectively relieves associated symptoms, including itching, burning, cracking, and scaling.

Dosage and Administration

Adults and children aged 12 years and older should begin treatment by washing the affected area with soap and water, ensuring it is dried completely before application. To use the product, the clear cap must be removed. The can should be held 4 to 6 inches away from the skin. A thin layer should be sprayed over the affected area once a day, either in the morning or at night, for a duration of 1 week or as directed by a healthcare professional. To stop the spray, the user should release the pressure on the nozzle. After each use, any excess product should be wiped from the spray opening, and the cap should be securely returned to the can. It is also important to wash hands thoroughly after each application.

For children under 12 years of age, it is advised to consult a doctor before use.

Contraindications

Use of this product is contraindicated in the following situations:

• Application on nails or scalp.

• Application in or near the mouth or eyes.

• Use for vaginal yeast infections.

Additionally, caution is advised to prevent eye contact; if contact occurs, rinse thoroughly with water. The product should not be punctured or incinerated, as it contains pressurized contents. Avoid exposure to heat or storage at temperatures exceeding 120°F (49°C).

Warnings and Precautions

This product is intended for external use only. It is contraindicated for application on nails or the scalp, and it should not be used in or near the mouth or eyes. Additionally, this product is not indicated for the treatment of vaginal yeast infections.

When utilizing this product, it is imperative to avoid contact with the eyes. In the event of eye contact, it is essential to rinse thoroughly with water. The product is under pressure; therefore, it must not be punctured or incinerated. Users should also refrain from exposing the product to heat or storing it at temperatures exceeding 120°F (49°C).

Healthcare professionals should advise patients to discontinue use and consult a physician if excessive irritation occurs or if the irritation worsens.

It is crucial to keep this product out of the reach of children. In the case of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center should be made without delay.

Side Effects

Patients using this product should be aware that it is intended for external use only. It is contraindicated for application on nails or the scalp, and it should not be used in or near the mouth or eyes, nor for the treatment of vaginal yeast infections.

During the use of this product, patients must take care to avoid contact with the eyes. In the event of eye contact, it is advised to rinse thoroughly with water. Additionally, patients should not puncture or incinerate the container, as it is under pressure. Exposure to heat or storage at temperatures exceeding 120°F (49°C) should be avoided.

Patients are advised to discontinue use and consult a healthcare professional if they experience excessive irritation or if the irritation worsens. It is also crucial to keep this product out of reach of children. In the case of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Lamisil at (terbinafine hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a healthcare professional before use. For adolescents and children aged 12 years and older, it is recommended to wash the affected area with soap and water, ensuring it is completely dry prior to application. The product should be sprayed on the affected area once daily, either in the morning or at night, for a duration of one week or as directed by a healthcare provider.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There are no specific statements regarding the use of Lamisil AT (terbinafine hydrochloride spray) during pregnancy. The prescribing information does not mention any safety concerns, contraindications, or special precautions related to the use of this product in pregnant patients. Additionally, no dosage modifications for pregnant individuals are provided. Healthcare professionals should consider the absence of data when advising women of childbearing potential regarding the use of this medication during pregnancy.

Lactation

Lactating mothers should consult a healthcare provider before using Lamisil AT (terbinafine hydrochloride) spray. There is a potential for excretion of terbinafine in breast milk. The effects of terbinafine on a nursing infant are not well studied; therefore, caution is advised.

Renal Impairment

Patients with renal impairment have no specific information regarding dosage adjustments, special monitoring, or safety considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of data necessitates careful clinical judgment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. It is imperative that healthcare providers remain vigilant and prepared to address any complications that may arise from an overdosage scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

Postmarketing experience has indicated that the following adverse reactions have been reported: rash, pruritus, and urticaria. These events were identified through voluntary reporting and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately.

It is important to inform patients not to allow the product to come into contact with their eyes. In the event of eye contact, patients should rinse their eyes thoroughly with water.

Additionally, healthcare providers should emphasize that patients must not puncture or incinerate the product, as it contains contents under pressure. Patients should be cautioned against exposing the product to heat or storing it at temperatures exceeding 120°F (49°C).

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled temperature range of 20° to 25°C (68° to 77°F) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature limits to prevent degradation.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Lamisil at, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)